Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
SAN DIEGO–(BUSINESS WIRE)–
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 11:10 a.m. Eastern Time.
A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at Acadia.com and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227537305/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
[email protected]
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Science Neurology Biotechnology Research Pharmaceutical Health Mental Health Clinical Trials
MEDIA:
| Logo |
 |